Fiona Marshall

Biography

 Fiona has a BSc in biochemistry from Bath University and a PhD in neuroscience from Cambridge University. She has more than 25 years' experience in drug discovery with particular expertise on GPCRs. She led the first group to show that GPCRs could form heterodimers and has published more than 80 peer-reviewed papers in the area of GPCRs. She spent 12 years at GlaxoWellcome/GlaxoSmithKline where she held a number of senior positions including Head of the Department of Molecular Pharmacology. She was Director of Discovery Pharmacology, Europe for Millennium Pharmaceuticals and then spent several years as an independent consultant to a variety of venture capital and biotech companies, including Inpharmatica, Merlion, Galapagos, Paradigm, Cancer Research Technology, Shire, CellAura, Bioimage, Chroma, Ablynx and Sentinel. Fiona is currently the chair of the MRC DPFS committee and is on the Translation Advisory Group of the Francis Crick Institute and on the Scientific Advisory board of Open Targets. She is also on the Board of Trustees of Alzheimer’s Research UK (ARUK) and on the ARUK Drug Discovery Alliance Advisory Group. Fiona won the 2012 WISE Women of Outstanding Achievement for Innovation and Entrepreneurship and received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry’s Biological and Medicinal Chemistry Sector, in recognition of her contribution to GPCR drug discovery. She was elected a Fellow of The Academy of Medical Sciences in 2016. Fiona is Executive VP and CSO of Sosei Group Corporation.

Research Interest

 biochemistry